QR Code

Levetiracetam for the treatment of mild cognitive impairment in Parkinson’s disease: a double-blind controlled proof-of-concept trial protocol

Abstract Background Mild memory impairment, termed amnestic mild cognitive impairment (aMCI), is associated with rapid progression towards dementia in Parkinson’s disease (PD). Studies have shown hyperactivation of hippocampal DG/CA3 subfields during an episodic memory task as a biomarker of aMCI re...

Full description

Saved in:
Main Authors: Nadeeka Dissanayaka, Dana Pourzinal, Gerard J. Byrne, Jihyun Yang, Katie L. McMahon, Gregory M. Pontone, John D. O’Sullivan, Robert Adam, Roberta Littleford, Mark Chatfield, Alexander Lehn, Zoltan Mari, Arnold Bakker
Format: Artigo
Language:Inglês
Published: BMC 2023-11-01
Series:Pilot and Feasibility Studies
Subjects:
Parkinson’s disease
Dementia
Levetiracetam
Episodic memory
fMRI
Hippocampus
Online Access:https://doi.org/10.1186/s40814-023-01406-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items